Drug Delivery Platforms
•229 stocks
•
Total Market Cap: Loading...
Apr 17, 2026
|
Medicus Pharma Files Orphan Drug Designation Application for SkinJect in Gorlin Syndrome
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (229)
| Company | Market Cap | Price |
|---|---|---|
|
BOLT
Bolt Biotherapeutics, Inc.
Bolt's Boltbody ISAC platform is a drug-delivery platform designed to deliver immune-stimulating payloads via antibodies.
|
$9.08M |
$4.87
+1.25%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Directly markets/provides a proprietary drug-delivery platform (D-MNA) enabling localized chemotherapy delivery.
|
$8.68M |
$0.35
+15.22%
|
|
RNAZ
TransCode Therapeutics, Inc.
TTX is a proprietary drug delivery platform for RNA therapeutics, enabling tumor targeting and intracellular delivery.
|
$8.07M |
$8.76
+0.63%
|
|
SYBX
Synlogic, Inc.
Synlogic positions its Synthetic Biotics as a Drug Delivery Platform enabling localized GI therapy.
|
$7.42M |
$1.05
+65.48%
|
|
PMCB
PharmaCyte Biotech, Inc.
PMCB's encapsulation technology is a drug-delivery platform enabling localized prodrug activation.
|
$7.38M |
$0.73
-0.19%
|
|
GELS
Gelteq Limited Ordinary Shares
Gelteq's core offering is a gel-based drug delivery platform used across nutraceuticals, pet care, sports, OTC, and pharmaceutical products.
|
$7.01M |
$0.74
-0.52%
|
|
SCNX
Scienture Holdings, Inc.
SCNX emphasizes novel formulations and delivery platforms (drug delivery platforms) as a competitive edge.
|
$6.94M |
$0.44
-1.77%
|
|
CELZ
Creative Medical Technology Holdings, Inc.
ImmCelz/AlloStem platform could be considered a Drug Delivery Platform for cell therapies.
|
$6.37M |
$2.42
+3.86%
|
|
ALUR
Allurion Technologies Inc.
Drug delivery platform angle via GLP-1 drug-eluting intragastric balloon; joint development.
|
$6.21M |
$0.68
-11.17%
|
|
MBRX
Moleculin Biotech, Inc.
MBRX utilizes liposomal drug delivery formulations for Annamycin, aligning with Drug Delivery Platforms as a major capability.
|
$6.03M |
$5.04
+0.80%
|
|
PULM
Pulmatrix, Inc.
Pulmatrix's core offering is the iSPERSE dry powder drug delivery platform, a direct product category.
|
$4.60M |
$1.24
-1.20%
|
|
ALZN
Alzamend Neuro, Inc.
AL001 uses a patented ionic cocrystal drug-delivery platform to improve brain lithium delivery.
|
$4.26M |
$1.11
+11.00%
|
|
TTNP
Titan Pharmaceuticals, Inc.
Titan's core ProNeura technology is a long-acting drug delivery platform used for subdermal implants.
|
$4.21M |
$4.61
|
|
SONN
Sonnet BioTherapeutics Holdings, Inc.
FHAB constitutes a proprietary drug delivery platform intended to extend half-life and improve tumor targeting of biologics.
|
$3.99M |
$1.28
+1.98%
|
|
OGEN
Oragenics, Inc.
ONP-002 uses a proprietary intranasal drug-delivery platform (powder formulation + breath-propelled device).
|
$3.77M |
$0.95
+2.56%
|
|
CLDI
Calidi Biotherapeutics, Inc.
Drug Delivery Platforms are at the core of RedTail/NeuroNova/SuperNova, enabling systemic delivery of therapeutic payloads to tumors.
|
$3.77M |
$0.77
+4.55%
|
|
LADX
LadRx Corporation
LADR is a proprietary drug delivery platform used to target tumors and release payloads.
|
$3.70M |
$0.11
|
|
ENTO
Entero Therapeutics, Inc.
Adrulipase is delivered via a capsule-based drug delivery approach; tag Drug Delivery Platforms captures the delivery modality as a core product attribute.
|
$3.65M |
$2.96
+22.31%
|
|
SILO
Silo Pharma, Inc.
Drug Delivery Platforms directly describes Silo's intranasal and implantable drug delivery technologies (SPC-15, SPC-14, SP-26).
|
$3.28M |
$0.34
-3.64%
|
|
PHGE
BiomX Inc.
BiomX leverages a drug delivery platform (BOLT) to rapidly assemble phage cocktails and targeted therapies.
|
$2.81M |
$1.80
-8.38%
|
|
KALA
KALA BIO, Inc.
MSC-S platform represents a drug delivery platform for cell-free therapies.
|
$2.67M |
$0.38
-5.27%
|
|
CLSD
Clearside Biomedical, Inc.
Clearside's core offering is a drug delivery platform enabling suprachoroidal (eye) delivery and extended-release formulations.
|
$2.15M |
$0.43
+4.90%
|
|
BICX
BioCorRx Inc.
BICX104 comprises a biodegradable, sustained-release naltrexone implant, representing a drug-delivery platform.
|
$2.02M |
$0.31
|
|
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The company references a proprietary platform designed to enhance drug delivery for radiation sensitization, indicating a drug delivery platform.
|
$1.98M |
$1.79
-2.97%
|
|
REVB
Revelation Biosciences, Inc.
Gemini is a drug-delivery platform formulation used across multiple indications, matching Drug Delivery Platforms.
|
$1.70M |
$1.15
-4.58%
|
|
LYRA
Lyra Therapeutics, Inc.
XTreo drug-delivery platform is Lyra's core product, enabling six months of localized drug therapy via in-office implant (LYR-210).
|
$1.66M |
$1.12
|
|
SIGY
Sigyn Therapeutics, Inc.
ChemoPrep/ChemoPure platforms imply drug-delivery optimization via extracorporeal circuits, fitting Drug Delivery Platforms.
|
$1.44M |
$0.08
|
|
NLSP
NLS Pharmaceutics AG
The company relies on proprietary drug-delivery platforms (extended-release mazindol formulation and DOXA platform) to optimize therapeutic profiles.
|
$748811 |
$0.79
-67.61%
|
|
NCNA
NuCana plc
ProTide is a proprietary drug-delivery platform used to enhance efficacy/safety of nucleoside analogs, a core differentiator for NuCana.
|
N/A |
$2.26
+6.10%
|
Showing page 3 of 3 (229 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
